Epilepsy
Regeneron Leads $66M Series B for Actio Biosciences’ Rare Disease Therapeutics
Regeneron; Actio Biosciences; rare diseases; Series B financing; KCNT1 inhibitor; TRPV4 inhibitor; ABS-1230; ABS-0871; Charcot-Marie-Tooth disease; epilepsy; orphan drug; clinical trials
Neurona nabs $102M to launch pivotal trial of epilepsy cell therapy
MTLE, Epilepsy, Cell Therapy, RMAT, Identifier, drug-resistant
Beyond the Diagnosis: Embracing the Humanity Behind Epilepsy Care
Patient-centered epilepsy care, Holistic epilepsy management, Quality of life in epilepsy, Empowering epilepsy patients, Multidisciplinary epilepsy treatment, Epilepsy patient experiences, Comprehensive epilepsy support
Biogen and Stoke Therapeutics Partner on Promising Dravet Syndrome Treatment
Biogen, Stoke Therapeutics, zorevunersen, Dravet syndrome, antisense oligonucleotide, rare epilepsy, drug development, pharmaceutical partnership
Axonis Secures $115 Million to Develop Novel Treatment for Drug-Resistant Pain and Epilepsy
Axonis Therapeutics, drug-resistant pain, epilepsy, CNS disorders, KCC2, GABA-related inhibition, series A funding
Breakthrough in Rare Childhood Epilepsies: Praxis’ Relutrigine Exceeds Efficacy Expectations
Praxis Precision Medicines, relutrigine, rare childhood epilepsies, epilepsy treatment, genetic epilepsy, precision medicine.
Takeda Faces $143M Loss After Epilepsy Drug Candidate Fails to Meet Expectations
Takeda, epilepsy drug, financial loss, pharmaceuticals, clinical trials
J&J Abandons Addex-Partnered Epilepsy Candidate After Phase II Failure
Addex Therapeutics, Johnson & Johnson, ADX71149, Epilepsy, Phase II Trial, Metabotropic Glutamate Receptor, Neurological Disorders
Takeda’s Soticlestat Misses Main Goal in Two Pivotal Epilepsy Studies
Soticlestat, Takeda, Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome, Phase 3 Trials, Seizure Frequency
Marinus Pharmaceuticals Reduces Workforce Amidst Challenges in Epilepsy Treatment Development
Marinus Pharmaceuticals, workforce reduction, epilepsy treatment, clinical trials, financial restructuring